CEFAZOLIN AND DEXTROSE (cefazolin sodium) by B. Braun is 12. Approved for respiratory tract infections due to streptococcus pneumoniae, staphylococcus aureus, streptococcus pyogenes in adults and 14 more indications. First approved in 2000.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
Cefazolin and Dextrose is a pre-filled IV injection combining cefazolin sodium (a first-generation cephalosporin) with dextrose for convenient administration. It is a bactericidal antibiotic that inhibits bacterial cell wall synthesis, indicated for respiratory, urinary, skin, biliary, bone, joint, genital infections, septicemia, endocarditis, and surgical prophylaxis across multiple patient populations.
Product is approaching loss of exclusivity with established market presence; commercial teams are likely focused on generic preparation and cost-containment strategies rather than growth initiatives.
12.1 Mechanism of Action Cefazolin is an antibacterial drug [see ]. 12.2 Pharmacodynamics The pharmacokinetic/pharmacodynamic relationship for cefazolin has not been evaluated in patients. 12.3 Pharmacokinetics Studies have shown that following intravenous administration of cefazolin to normal…
Worked on CEFAZOLIN AND DEXTROSE at B. Braun? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Pharmacokinetics and Safety of Cefazolin 3gm DUPLEX in Adults
Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects
Pediatric Cefazolin PK Study
Pharmacokinetics and Safety of Cefazolin 2g in DUPLEX
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on cefazolin and dextrose offers exposure to mature injectable antibiotic management, reimbursement strategy, and generic defense—high-value skills in cost-containment-focused healthcare. However, the LOE-approaching lifecycle means limited growth upside; roles are better suited for professionals seeking operational expertise in a defensive, margin-focused environment rather than commercial expansion.